System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Johannes Levin is an expert in Neurology at Munich Cluster for Systems Neurology (Germany). As of October 2026, ScienceLeadR ranks Johannes Levin in the top 1% of experts worldwide for Dementia, Alzheimer Disease and Neurocognitive Disorders. Johannes Levin has authored 628 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 10 of them ongoing. SLR score: 2,058 (community average: 125). How the SLR is computed.

LeadR Profile

Johannes Levin Munich Cluster for Systems Neurology Germany
2 058 ScienceLeadR Reputation 2058

Unlock

Register Login
Network Map

Neurology

Subspecialties: Psychiatry - Biochemistry - Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Ludwig-Maximilians-Universität München

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 628

Citations

Citations: 19 166 1st author: 28 Last author: 49 Unique author: 5

Main journals

Alzheimers Dement 118
Mov Disord 26
J Neurol 23
Brain 22
Neurology 20

Best Journals

Lancet Neurol 13
Nat Med 6
N Engl J Med 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Microglial dynamics associate with the spatial pattern of tau deposition in early Alzheimer's disease.
PMID 42875788 — alzheimer disease, brain, amyloid		Alzheimers Res Ther20260
Gantenerumab reduces brain amyloid-β proteoforms: Biochemical evaluation in dominantly inherited Alzheimer disease.
PMID 42856312 — immunization, plaque, amyloid, antibodies, alzheimer disease, tomography, positron-emission tomography, brain, pathology, biomarkers, antibodies, monoclonal, therapeutics, amyloid, tissues, immunization, passive		medRxiv20260
Network-dependent remote effects and local tau burden jointly shape neuronal dysfunction in Alzheimer's disease.
PMID 42842336 — dementia, alzheimer disease, brain, cognitive dysfunction		Alzheimers Dement20260
Hybrid multimodal late fusion frameworks for bvFTD classification in imbalanced dementia datasets.
PMID 42818882 — dementia, brain, classification, magnetic resonance imaging, neurodegenerative diseases		Front Aging Neurosci20260
Dynamic [ 18F]PI-2620 recording facilitates prediction of β-amyloid positivity and simultaneous staging of tau and neurodegeneration.
PMID 42791560 — tauopathies, predictive value of tests, biomarkers, amyloid		Mol Neurodegener20260

Clinical Studies 19

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

Phase 2 4
Phase 2/Phase 3 4
Early Phase 1 3
Phase 3 3
N/A 2
Phase 4 2
Phase 1 1

By status:

Recruiting 8
Active not recruiting 5
Completed 4
Unknown 2

By type:

Interventional 17
Observational 2

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 2
multicentric5to9 0
multicentricup10 12

Main Topics

Cohort/Consortium Investigators 10

Ongoing Clinical Trials

10 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer s Disease (MCI to Mild Dementia Due to AD)
2024-518006-40-00 — dementia, safety, alzheimer disease		Phase 3Active not recruiting2025
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer s Disease (MCI to Mild Dementia Due to AD)
2024-518008-33-00 — dementia, safety, alzheimer disease		Phase 3Active not recruiting2025
Patient and care related benefits of amyloid PET imaging (ENABLE)
2023-503705-10-00 — dementia, dementia, multi-infarct, parkinson disease, alzheimer disease, positron-emission tomography, multiple chronic conditions, dementia, vascular, hiv, viruses, creutzfeldt-jakob syndrome, amyloid, pick disease of the brain, huntington disease		Phase 4Recruiting2024
A Study of Treatments for the Prevention of Disease Progression in Individuals at Risk for or With Early Onset Alzheimer s Disease Caused by a Genetic Mutation
2024-517187-36-01 — therapies, investigational, alzheimer disease, disease progression, primary prevention, therapeutics, mutation		Phase 2/Phase 3Recruiting2026
Test retest Trial With 11C MODAG 005 in PD or MSA and AMHC Pilot Phase
NCT07640542 — injections, pilots, lewy bodies, safety, atrophy, multiple system atrophy, parkinson disease, tomography, positron-emission tomography, brain, positron emission tomography computed tomography, nerve degeneration, shy-drager syndrome, alpha-synuclein, synucleins		Early Phase 1Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS